<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01468740</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-HL 2004</org_study_id>
    <nct_id>NCT01468740</nct_id>
  </id_info>
  <brief_title>Prospective Study on HIV-related Hodgkin Lymphoma</brief_title>
  <official_title>A Prospective Multicenter Study on HIV-associated Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harlachinger Krebshilfe e.V.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche AIDS Gesellschaft e.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harlachinger Krebshilfe e.V.</source>
  <brief_summary>
    <textblock>
      Standard therapy for HIV-related Hodgkin lymphoma (HIV-HL) has not been defined. This trial
      was initiated to investigate a risk adapted treatment strategy in patients (pts) with HIV-HL
      as established in HIV-negative patients with HL.

      Treatment schedule:

        -  Early stage favorable Hodgkin Lymphoma (HL): 2 cycles of doxorubicin, bleomycin,
           vinblastine, and dacarbazine (ABVD) plus 30 Gy involved field (IF) radiation

        -  Early stage unfavorable HL: 4 cycles of bleomycin, etoposide, doxorubicin,
           cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline or 4
           cycles of ABVD plus 30 Gy IF radiation

        -  Advanced HL: 8 cycles of BEACOPP-baseline. BEACOPP should be replaced by ABVD in pts
           with far advanced HIV-infection. After the completion of chemotherapy sites of initial
           bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in
           diameter receive 30 Gy of irradiation.

        -  Primary outcome measure: tolerability, treatment-related mortality

        -  Secondary outcome measure: complete remission rate, progression-free survival (PFS),
           overall survival (OS).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2004</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with World Health Organization (WHO) grade 3 and grade 4 toxicity</measure>
    <time_frame>30 days after termination of chemotherapy or radiotherapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment related mortality</measure>
    <time_frame>30 days after termination of chemotherapy or radiotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months and 24 months after termination of chemotherapy or radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>12 months and 24 months after termination of chemotherapy or radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>30 days and 90 days after termination of chemotherapy or radiotherapy</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>HIV-associated Hodgkin Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain doxorubicin.
Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin</intervention_name>
    <description>The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain bleomycin.
Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <description>The four-drug ABVD chemotherapy regimen contains vinblastine
Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>The four-drug ABVD chemotherapy regimen contains dacarbazine
Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>The seven-drug BEACOPP-baseline chemotherapy regimen contains etoposide.
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>The seven-drug BEACOPP-baseline chemotherapy regimen contains cyclophosphamide.
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>The seven-drug BEACOPP-baseline chemotherapy regimen contains vincristine.
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procarbazine</intervention_name>
    <description>The seven-drug BEACOPP-baseline chemotherapy regimen contains procarbazine.
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>The seven-drug BEACOPP-baseline chemotherapy regimen contains prednisone.
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 - 75 years

          -  proven infection with HIV 1 (Elisa and Western Blot)

          -  histology-proven newly diagnosed Hodgkin lymphoma

          -  written, informed consent.

        Exclusion Criteria:

          -  severe cardiac, hepatic or pulmonary insufficiency

          -  severe renal insufficiency (creatinine &gt; 2,0 mg/dl) not caused by lymphoma

          -  bone marrow failure, not caused by lymphoma or HAART (neutrophils &lt; 1000/µl, platelets
             &lt; 70.000/µl)

          -  uncontrolled infection

          -  uncontrolled drug addiction or psychiatric disease

          -  pregnancy or lactation period

          -  prior chemotherapy of Hodgkin lymphoma

          -  life expectancy &lt; 6 weeks

          -  HIV-related wasting-syndrome

          -  active secondary malignancy with cervix carcinoma in situ, basalioma and Kaposi`s
             sarcoma being excepted
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Hentrich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harlaching Hospital, Academic Teaching Hospital of the University of Munich, Department of Hematology, Oncology and Palliative Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcus Hentrich, MD</last_name>
    <phone>0049 89 6210 2663</phone>
    <email>marcus.hentrich@klinikum-muenchen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vivantes Auguste Victoria Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Müller, MD</last_name>
      <phone>0049 30 130 20 2321</phone>
      <email>Markus.Mueller2@vivantes.de</email>
    </contact>
    <contact_backup>
      <last_name>Marcel Berger, MD</last_name>
      <phone>0049 30 130 20 2321</phone>
      <email>Marcel.Berger@vivantes.de</email>
    </contact_backup>
    <investigator>
      <last_name>Markus Müller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcel Berger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keikawus Arasteh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ärzteforum Seestrasse</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Siehl, MD</last_name>
      <phone>0049 30 455095-0</phone>
      <email>jan.siehl@aerzteforum-seestrasse.de</email>
    </contact>
    <investigator>
      <last_name>Jan Siehl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universiy of Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juergen Rockstroh, MD</last_name>
      <phone>0049 228 287 16558</phone>
      <email>Rockstroh@uni-bonn.de;</email>
    </contact>
    <investigator>
      <last_name>Jürgen Rockstroh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Wyen, MD</last_name>
      <phone>0049 221 478 88835</phone>
      <email>christoph.wyen@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Gerd Fätkenheuer, MD</last_name>
      <phone>0049 221 478 4886</phone>
      <email>g.faetkenheuer@uni-koeln.de</email>
    </contact_backup>
    <investigator>
      <last_name>Christoph Wyen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerd Fätkenheuer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timo Wolf, MD</last_name>
      <phone>0049 69 6301 5452</phone>
      <email>Timo.Wolf@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Timo Wolf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinikum St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maike Nickelsen, MD</last_name>
      <phone>0049 40 18 18 85 20 05</phone>
      <email>m.nickelsen@asklepios.com</email>
    </contact>
    <investigator>
      <last_name>Maike Nickelsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infektionsmedizinisches Zentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Hoffmann, MD</last_name>
      <phone>0049 40 4132420</phone>
      <email>hoffmann@ich-hamburg.de;</email>
    </contact>
    <investigator>
      <last_name>Christian Hoffmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harlaching Hospital</name>
      <address>
        <city>Munich</city>
        <zip>81545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Hentrich, MD</last_name>
      <phone>0049 89 6210 2663 or 2731</phone>
      <email>marcus.hentrich@klinikum-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Marcus Hentrich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2011</study_first_submitted>
  <study_first_submitted_qc>November 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <last_update_submitted>November 7, 2011</last_update_submitted>
  <last_update_submitted_qc>November 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

